Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
NACHT domain
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "NACHT domain" in MCE Product Catalog:
51
51 Publications Verification
Target:
Research Areas:
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .
3
3
3 Cited Publications
Cat. No.: HY-N6893
CAS No.: 54999-07-4
3
3 Cited Publications
Cat. No.: HY-N1431A
CAS No.: 29479-00-3
1
1 Cited Publications
Target:
Research Areas:
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .
Cat. No.: HY-162333
CAS No.: 2842012-69-3
Research Areas:
BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity .
Cat. No.: HY-179024
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NP3-742 is an orally active NLRP3 inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC50s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis .
Cat. No.: HY-145087
CAS No.: 210826-47-4
Synonyms: NLRP3-IN-5
Research Areas:
NP3-146 is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 shows potent inhibitory activity against IL-1β release with an IC50 value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 can be used for the research of inflammatory diseases .
Cat. No.: HY-172134
CAS No.: 1997362-01-2
Target:
Research Areas:
NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis .
Research Areas:
NP3-146 sodium is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 sodium shows potent inhibitory activity against IL-1β release with an IC50 value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 sodium regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 sodium can be used for the research of inflammatory diseases .
Cat. No.: HY-182778
Target:
Research Areas:
Anti-inflammatory agent 114 is an anti-inflammatory agent. Anti-inflammatory agent 114 binds to the allosteric inhibitory pocket in the NLRP3 NACHT domain. Anti-inflammatory agent 114 inhibits the expression of iNOS, COX-2 and NLRP3. Anti-inflammatory agent 114 can be used for the research of inflammatory diseases .
Cat. No.: HY-183296
Research Areas:
NLRP3-IN-91 is a potent NLRP3 inflammasome inhibitor with a Kd of 558.4 nM. NLRP3-IN-91 directly targets the NLRP3 NACHT domain, blocks inflammasome assembly and activation, and exerts anti-inflammatory effects. NLRP3-IN-91 increases survival time in a murine model of LPS (HY-D1056)-induced sepsis. NLRP3-IN-91 can be used for the research of sepsis .
Cat. No.: HY-181488
CAS No.: 3097745-69-9
Research Areas:
NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a Kd of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU (HY-B2130A)-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout .
Cat. No.: HY-184651
CAS No.: 3055155-53-5
Research Areas:
NLRP3-IN-93 is an orally active, blood-brain barrier-permeable NLRP3 inhibitor. NLRP3-IN-93 binds to the NACHT domain, blocks inflammasome assembly, and inhibits downstream IL-1β release, without significantly inhibiting various CYP isoforms. NLRP3-IN-93 demonstrates dose-dependent efficacy in mouse models of acute inflammation and Parkinson's disease, and exhibits good tolerability and an acceptable safety window in rats and dogs. NLRP3-IN-93 can be used in research on Parkinson's disease .
Cat. No.: HY-103666R
CAS No.: 1073612-91-5
Research Areas:
CY-09 (Standard) is the analytical standard of CY-09 (HY-103666). This product is intended for research and analytical applications. CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .
Cat. No.: HY-P87287
Synonyms: and NACHT-containing protein antibody; CARD 12 antibody; CARD antibody; CARD LRR and NACHT containing protein 1 antibody; CARD LRR and NACHT containing protein antibody; CARD12 antibody; Caspase recruitment domain containing protein 12 antibody; Caspase recruitment domain family member 12 antibody; Caspase recruitment domain-containing protein 12 antibody; CLAN 1 antibody
Cat. No.: HY-P702188
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NLRP1; NACHT; LRR and PYD domains-containing protein 1; Caspase recruitment domain-containing protein 7; Death effector filament-forming ced-4-like apoptosis protein; Nucleotide-binding domain and caspase recruitment domain
Cat. No.: HY-P702189
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NLRP1; NACHT; LRR and PYD domains-containing protein 1; Caspase recruitment domain-containing protein 7; Death effector filament-forming ced-4-like apoptosis protein; Nucleotide-binding domain and caspase recruitment domain
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
